Granzyme B/GZMB Protein, Human (HEK293, His)

Granzyme B (GZMB) is a cytosolic protease abundant in cytotoxic T-cells and natural killer cells, pivotal for immune defense. Delivered into target cells, GZMB activates caspase-independent pyroptosis by cleaving gasdermin-E (GSDME). This triggers pyroptosis, leading to target cell death. GZMB exhibits substrate specificity for aspartate residue cleavage and contributes to an activation cascade of caspases (3, 9, 10), impacting apoptosis execution. Involved in bacterial infection response, GZMB cleaves and activates caspase-7, promoting plasma membrane repair. Its multifaceted activities underscore its crucial role in immune responses and cellular defense. Granzyme B/GZMB Protein, Human (HEK293, His) is the recombinant human-derived Granzyme B/GZMB protein, expressed by HEK293, with C-His labeled tag. The total length of Granzyme B/GZMB Protein, Human (HEK293, His) is 247 a.a., with molecular weight of 35-40 kDa.

Granzyme B (GZMB) is a highly abundant protease residing in the cytosolic granules of cytotoxic T-cells and natural killer cells, playing a pivotal role in immune defense mechanisms. Upon delivery into the target cell through the immunological synapse, GZMB activates caspase-independent pyroptosis by catalyzing the cleavage of gasdermin-E (GSDME). This results in the release of the pore-forming moiety of GSDME, triggering pyroptosis and ultimately leading to target cell death. GZMB exhibits a substrate specificity for cleavage after aspartate residues. Additionally, it is implicated in an activation cascade of caspases, including caspase-3, -9, and -10, thereby contributing to apoptosis execution. Moreover, GZMB is involved in the response to bacterial infection, where it cleaves and activates caspase-7, promoting plasma membrane repair. The multifaceted activities of GZMB highlight its crucial role in orchestrating immune responses and cellular defense mechanisms.

Measured by its ability to cleave a peptide substrate, t-Butyloxycaronyl-Ala-Ala-Asp-ThioBenzylester (Boc-AAD-SBzl), in the presence of 5,5’-Dithio-bis (2-nitrobenzoic acid) (DTNB) and the specific activity is ≥1500 pmol/min/μg. Note: The enzyme needs to be activated by Active Cathepsin C.

Human

HEK293

C-His

P10144 (M1-Y247)

3002  [NCBI]

35-40 kDa

Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.